The Institute for Clinical Immuno-Oncology (ICLIO) is conducting a survey to better understand the barriers and challenges that cancer programs experience in accessing innovative immuno-oncology (I-O) therapies.

Your participation will provide valuable insight that ICLIO and other oncology stakeholders will use to foster discussion around value and access to immunotherapies, with the aim of developing potential solutions.

It should take no more than 5 minutes to complete this survey.

Thank you for making your voice heard.


* 1. Contact Information: (All reported data is confidential and will remain anonymous)

* 2. What is your role at your institution?

* 3. What is your practice setting? (select one)

Section I: Clinical and Policy Issues in Immuno-Oncology (I-O)

* 4. To the best of your ability, please rate your staff’s current knowledge with regards to the following clinical characteristics of immuno-oncology (I-O). (1 = little to no knowledge, 5 = very knowledgeable)

  1 2 3 4 5
I-O mechanisms of action
I-O indications (specific tumor types treated)  
Response assessment to I-O therapy
I-O sequencing considerations (1st line, 2nd line, 3rd line)
Use of I-O biomarkers        

* 5. Does your institution have a specific I-O program and/or workspace in place to diagnose and manage immune-related adverse events?